These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1. Eckert K; Grünberg E; Immenschuh P; Garbin F; Kreuser ED; Maurer HR J Cancer Res Clin Oncol; 1997; 123(8):420-8. PubMed ID: 9292704 [TBL] [Abstract][Full Text] [Related]
28. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906 [TBL] [Abstract][Full Text] [Related]
29. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. Naume B; Gately M; Espevik T J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169 [TBL] [Abstract][Full Text] [Related]
30. Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures. Vollenweider I; Moser R; Groscurth P Cancer Immunol Immunother; 1994 Nov; 39(5):305-12. PubMed ID: 7987862 [TBL] [Abstract][Full Text] [Related]
31. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes. Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597 [TBL] [Abstract][Full Text] [Related]
32. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Ayello J; van de Ven C; Fortino W; Wade-Harris C; Satwani P; Baxi L; Simpson LL; Sanger W; Pickering D; Kurtzberg J; Cairo MS Biol Blood Marrow Transplant; 2006 Jun; 12(6):608-22. PubMed ID: 16737934 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of lymphokine-activated killer cells by human pulmonary macrophages: discordance between up-regulation of the beta chain (p75) of the interleukin-2 receptor on CD56+ cells and limited response to interleukin-2. Yarbrough WC; Wilkes DS; Weissler JC Am J Respir Cell Mol Biol; 1994 Feb; 10(2):184-91. PubMed ID: 7509162 [TBL] [Abstract][Full Text] [Related]
34. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy. Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272 [TBL] [Abstract][Full Text] [Related]
35. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. Tilden AB; Itoh K; Balch CM J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627 [TBL] [Abstract][Full Text] [Related]
36. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells. Atzpodien J; Gulati SC Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310 [TBL] [Abstract][Full Text] [Related]
37. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. Alderson MR; Sassenfeld HM; Widmer MB J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722 [TBL] [Abstract][Full Text] [Related]
38. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma. Muralikrishna K; Varalakshmi C; Khar A Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244 [TBL] [Abstract][Full Text] [Related]
39. Generation of lymphokine-activated killer cell activity from human thymocytes. Ramsdell FJ; Golub SH J Immunol; 1987 Sep; 139(5):1446-53. PubMed ID: 2442246 [TBL] [Abstract][Full Text] [Related]